Biomarker for Gaucher Disease (BioGaucher)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01331642
Recruitment Status : Terminated (the Albrecht Kossel Institute of University Rostock terminated participation in the study conduct; Study Sponsorship is moved to Centogene AG)
First Posted : April 8, 2011
Last Update Posted : July 2, 2018
Centogene AG Rostock
Information provided by (Responsible Party):
Prof. Dr. Arndt Rolfs, University of Rostock

Brief Summary:
Gaucher disease is an autosomal recessive hereditary lysosomal storage disorder. Occurrence of the disease is due to a hereditary deficiency of the Glucocerebrosidase, a lysosomal enzyme which divides Glucocerebroside in to Glucose and Ceramides.

Condition or disease
Lysosomal Storage Diseases Gaucher Disease Sphingolipidoses

Detailed Description:

The unmetabolised Glucocerebrosides are stored throughout the whole reticulo-endothelial system. Accumulation of Glycolipid-enriched Macrophages establishes a pathoanatomical phenomenon, the so-called Gaucher cells, which can be verified by light microscopy. Activation markers of the Macrophages, like the enzyme Chitotriosidase or CCL18, are parameters which follow the course of Gaucher dis-ease. Gaucher disease is the most frequently inherited Sphingolipidosis in the general population, and in Ahskenazi Jews, in who the prevalence is much higher (1:450). The gene which codes the Glucocerebrosidase is on the long arm of chromosome 1 and covers 11 exons. So far, more than 200 different mutations in Gaucher patients have been described, mostly missense mutations. In addition frame-shift- and splice-site-mutations have been detected, as well as insertions and deletions. More frequent mutations are N370S, L444P, IVS2+1G>A, c.84insG, R463C and R496H [Sidransky E. 2004]. The clinical appearance is heterogeneous. The classical phenotype is characterized by visceral organ (Hepatosplenomegaly) and skeleton system (Bone marrow infiltrates up to bone infarcts and pathological fractures) affection. Moreover, consecutive blood cell count changes, Anemia and Thrombocytopenia are reported.A serious distinction lies in the appearance of neurological manifestations (myoclonus epilepsy, hydrocephalus, ocular movement disturbances). There is discussion on whether the classification into the typical three disease types (type1: non-neuronopathic progress form, type2: acute neuronopathic progress form, type3: chronic neuronopathic progress form) is still up-to-date, since it does not sufficiently reflect the reality of the clinical presentation. A clear genotype-phenotype relationship does not exist. The same DNA mutations are detected in patients with pronounced differences in disease progression. The exception is the mutation N370S, which has so far been detected in connection with only visceral progress forms (type1) [Koprivica et al. 2000]. At least the outcome of the non-neuronopathic disorder cases could be improved by the introduction and general availability of enzyme therapy. Under this kind of therapy there is a reduction of liver and spleen size as well as a normalization of the haemogram parameters.

New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity. The development of new bio-chemical markers from the plasma of the affected patients is the goal of the study.

Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : April 2011
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Patients from the first day of life with Gaucher Disease based on biochemical and/or genetic criteria or high-grade suspicion for Gaucher disease.

Primary Outcome Measures :
  1. Development of a new MS-based biomarker for the early and sensitive diagnosis of Gaucher Disease from plasma [ Time Frame: 24 month ]

Secondary Outcome Measures :
  1. Testing for clinical robustness, specificity and long-term stability of the biomarker [ Time Frame: 24 month ]

Biospecimen Retention:   Samples With DNA
For the development of the new biomarkers using the technique of Mass-spectometry 5ml EDTA blood and a dry blood spot filter card are taken. To proof the correct Gaucher diagnosis in those patients where up to the enrollment in the study no genetic testing has been done, sequencing of Gaucher will be done. The analyses are done in the Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Gaucher Disease based on biochemical and/or genetic criteria or high-grade suspicion for Gaucher disease.

Inclusion Criteria:

  • Informed consent will be obtained from the patient or the parents before any study related procedures.
  • Patients from the first day of life
  • The patient has a diagnosis of Gaucher Disease based on biochemical and/or genetic criteria or high-grade suspicion for Gaucher disease

High-grade suspicion present, if one or more inclusion criteria are valid:

  • Positive family anamnesis for Gaucher disease
  • Splenomegaly without identifiable cause
  • Hepatomegaly without identifiable cause
  • Anemia or thrombocytopenia without identifiable cause CNS involvement without identifiable cause

Exclusion Criteria:

  • No Informed consent from the patient or the parents before any study related procedures
  • No diagnosis of Gaucher disease or no valid criteria for profound suspicion of Gaucher disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01331642

Pediatric practice
Oran, Algeria, 31000
Health Technology Assessment in Clinical Genetics Research Group
Porto Alegre -RS, Brazil, 90035-003
Clinics Hospital of Ribeirao Preto- University of Sao Paulo
Sao Paulo, Brazil, 14048-900
University of Rostock, Albrecht-Kossel Institute
Rostock, Germany, 18147
Aristotle University of Thessaloniki-Ippokration General Hospital
Thessaloniki, Greece, 54642
NIRMAN, University of Mumbai
Mumbai, India, 400705
Mother and Child Health Institute of Serbia
Novi-Beograd, Serbia, 11070
Sponsors and Collaborators
University of Rostock
Centogene AG Rostock
Principal Investigator: Arndt Rolfs, MD University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration

Responsible Party: Prof. Dr. Arndt Rolfs, University of Rostock Identifier: NCT01331642     History of Changes
Other Study ID Numbers: BG05/2011
First Posted: April 8, 2011    Key Record Dates
Last Update Posted: July 2, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Prof. Dr. Arndt Rolfs, University of Rostock:
Lymphatic Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Gaucher Disease
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Metabolic Diseases
Lipid Metabolism Disorders
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors